22,477 Shares in Moderna, Inc. $MRNA Acquired by AXQ Capital LP

AXQ Capital LP purchased a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,477 shares of the company's stock, valued at approximately $1,574,000.

Other institutional investors also recently modified their holdings of the company. Louisiana State Employees Retirement System bought a new stake in Moderna during the first quarter valued at $899,000. Merck & Co. Inc. bought a new position in shares of Moderna in the 2nd quarter worth about $161,642,545. Bank of New York Mellon Corp acquired a new position in shares of Moderna in the 2nd quarter valued at about $119,168,000. Contravisory Investment Management Inc. lifted its stake in shares of Moderna by 1,387.6% in the 2nd quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company's stock valued at $1,696,000 after purchasing an additional 22,590 shares during the period. Finally, Lingotto Investment Management LLP boosted its position in shares of Moderna by 33.7% during the 4th quarter. Lingotto Investment Management LLP now owns 498,693 shares of the company's stock valued at $14,706,000 after purchasing an additional 125,598 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Insider Buying and Selling

In related news, President Stephen Hoge sold 53,336 shares of the company's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares of the company's stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Loop Capital set a $135.00 price target on Moderna in a research note on Wednesday, August 19th. Jefferies Financial Group reiterated a "hold" rating on shares of Moderna in a research note on Wednesday, August 19th. Argus upgraded shares of Moderna from a "hold" rating to a "buy" rating and set a $180.00 target price on the stock in a research report on Friday, August 28th. Royal Bank Of Canada reissued a "sector perform" rating and set a $130.00 target price on shares of Moderna in a research note on Wednesday, August 19th. Finally, JPMorgan Chase & Co. raised their price target on shares of Moderna from $40.00 to $77.00 and gave the stock an "underweight" rating in a report on Friday, August 21st. Seven research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat.com, Moderna has an average rating of "Hold" and an average price target of $76.72.

Moderna Stock Down 2.2%

MRNA stock opened at $145.55 on Friday. The stock has a fifty day moving average of $85.75 and a 200-day moving average of $63.45. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $176.66. The company has a market capitalization of $58.11 billion, a price-to-earnings ratio of -18.22 and a beta of 1.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to analysts' expectations of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.13) EPS. As a group, equities research analysts predict that Moderna, Inc. will post -6.09 earnings per share for the current year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its primary recurrence-free-survival endpoint in resected stage IIB–IV melanoma. It was the first positive Phase 3 result for an mRNA-based cancer therapy and strengthens Moderna’s long-term oncology outlook, although detailed data have not yet been released. Moderna melanoma trial article
• Positive Sentiment: Technical analysts describe the recent consolidation as a potential bullish pennant following the cancer-vaccine-driven breakout. Elevated short interest could provide additional buying pressure if the shares break above resistance. Moderna technical forecast
• Neutral Sentiment: Chief Legal Officer Shannon Klinger sold 3,471 shares for approximately $486,000 under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards. Because the transaction was planned and tax-related, it provides limited insight into management’s view of Moderna’s valuation.
• Negative Sentiment: Rothschild & Co. Redburn downgraded Moderna from Neutral to Sell, saying the cancer-vaccine rally has made the stock overvalued. The firm raised its price target to $81 from $40, but the new target remains well below recent trading levels, intensifying profit-taking concerns. Rothschild Moderna downgrade
• Negative Sentiment: GSK is advancing an mRNA influenza vaccine toward Phase 3 after reporting stronger immune responses in Phase 2. The competing program could challenge Moderna’s newly approved mFlusiva and increase pressure on its commercial vaccine pipeline. GSK mRNA flu vaccine competition

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source